Latest News and Press Releases

60 Degrees Pharma partners with Yale to develop tafenoquine for treating and preventing babesiosis, a severe tick-borne disease with limited treatments.

60 Degrees Pharma will import KODATEF® from Australia to ensure U.S. tafenoquine supply, addressing rising ARAKODA® demand.

60 Degrees Pharmaceuticals announces IRB approval for Phase II study of tafenoquine for chronic babesiosis, with enrollment starting Q3 2025.

60 Degrees Pharma (Nasdaq: SXTP) begins enrolling patients in a clinical study to evaluate tafenoquine for persistent, relapsing babesiosis treatment.

60 Degrees Pharma and Tufts MC partner to develop tafenoquine for babesiosis, co-own patents, and aim for FDA approval to address unmet medical needs.

60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs.

60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings report.

60 Degrees Pharmaceuticals launches a pilot to boost ARAKODA® awareness, focusing on virtual sales and a co-pay program for malaria prevention.

60 Degrees Pharma Q2 2024 net product revenues doubled YoY to $125K, with an 18.3% sequential growth. Gross profit rose to $35K from a $124K loss.

60 Degrees Pharma grants U of Kentucky a right of reference to ARAKODA® NDA for a Phase IIb trial combining SJ733 with tafenoquine to treat vivax malaria.